ArticlePloS one2026
The association of eicosanoids with lung structure and function: Findings from the Multi-Ethnic Study of Atherosclerosis lung study and Framingham Heart Study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEicosanoids are bioactive signaling lipids that have roles in airway remodeling, smooth muscle hypertrophy, emphysema and pulmonary fibrosis via mediation of pro- and anti-inflammatory pathways. Specific eicosanoids have been associated with lung diseases such as asthma and pulmonary fibrosis, yet their association with lung function more broadly is not completely understood. We aimed to investigate the association of eicosanoids and related metabolites with early changes in lung function and structure.
methodsWe performed comprehensive profiling of over 250 eicosanoids and eicosanoid-related metabolites using directed non-targeted mass spectrometry in the Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study with independent validation in the Framingham Heart Study (FHS). We performed cross-sectional analysis of the associations between metabolites and lung function as assessed by spirometry and quantitative lung measures on computed tomography (CT).
resultsAmong 3384 participants (mean age 63 ± 10 years, 51% women), 51 metabolites were associated with lung function in MESA Lung (22 with % predicted FEV1, 18 with % predicted FVC, and 25 with FEV1/FVC ratio), with 24 validated among FHS participants. Of these 51 metabolites, 27 were associated with obstructive lung physiology, including linoleic acid derivatives (9-HODE) and other long-chain fatty acids (hydroxyhexadecanoic acid, hydroxyoctadecanoic acid) associated with higher odds. Fourteen metabolites were associated with restrictive physiology, including putative dihydroxy-20:3 and an LTB3 analog associated with lower odds, and omega-3 fatty acids (EPA, stearidonic acid) associated with higher odds.
conclusionsSpecific eicosanoids and eicosanoid-related metabolites including linoleic acid derivatives and long-chain fatty acids were associated with obstructive, and leukotrienes and omega-3 fatty acids with restrictive lung physiology. These findings highlight bioactive lipids involved in both pro- and anti-inflammatory pathways as potential influencers of lung function and may serve as future therapeutic targets early in lung disease development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.